Short Summary
Genentech appealed the rejection of its patent application for a medicinal compound, 'Inhibitors of IAP', by the Controller. The Controller rejected the claims citing lack of novelty and inventive step under various sections of the Patents Act. The High Court allowed the appeal, finding the Controller's objections farfetched.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Madras High Court. Understanding the court's reasoning in Genentech, Inc. vs Controller of Patents and Designs is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Shilpa Shetty KundravsGetoutlive.in & Ors.
Shilpa Shetty Kundra filed an Interim Application alleging that unknown persons used her photographs to generate and circulate obscene, sexually explicit deepfake content created via artificial intelligence. She sought immediate orders to remove all infringing content from online platforms due to the severe damage to her reputation and dignity. The Court passed an interim order directing all defendants to delete the specified URLs and instructing government bodies (MeitY and DoT) to pull down the unlawful content.
University College LondonvsThe Assistant Controller of Patents and Designs
University College London appealed an order rejecting its divisional patent application concerning 'A Delayed Release Drug Formulation.' The core dispute centered on whether the complete specification of the parent application related to more than one invention, which was the basis for rejection. The appellant argued that their claims were distinct and did not constitute double patenting. The Madras High Court set aside the impugned order and remanded the matter back to the Controller for reconsideration.
Provivi, Inc.vsThe Controller Of Patents And Designs
Provivi, Inc. challenged an order of refusal dated 30.05.2023 passed by The Controller of Patents and Designs regarding its patent application. The Petitioner argued that the Impugned Order summarily rejected the application without examining the submissions made in response to the First Examination Report (FER).
Novartis AGvsMedipol Pharmaceuticals India Pvt Ltd
Novartis AG filed a suit seeking permanent injunction against Medipol Pharmaceuticals India Pvt Ltd and Metrochem Api Private Limited for infringing its patent (No. 233161) covering 'Eltrombopag Olamine', the API in Revolade. The court found that both defendants acknowledged the validity of the patent and admitted they had not manufactured or commercially sold the patented product, leading to a decree granting permanent injunction during the patent's term.
F- Hoffmann -La Roche AgvsZydus Lifesciences Limited
F- Hoffmann -La Roche filed a suit for infringement against Zydus Lifesciences Limited concerning two patents related to Pertuzumab, a monoclonal antibody used in cancer treatment. The court issued several procedural orders and directed both parties to provide exhaustive legal and scientific assistance, including disclosing experts and considering an independent Scientific Advisor, while the core issue of formulation identity remains pending.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.